Skip to main content
. 2010 Feb 6;36:14. doi: 10.1186/1824-7288-36-14

Table 3.

Characteristics and treatment of CSA related neurotoxicity

Patient number #1 #2 #3 #4 #5 #6
Day of onset post HSCT 1 5 40 20 7 15

CSA levels (ng/ml) 69 250 194 179 177 150

Mg levels (mEq/l) 0.88 0.86 0.95 0.72 0.85 1.03

Cholesterol and
tryglicerides levels (mg/dl)
123/82 152/64 125/137 195/139 136/162 177/79

Prodromes headache & vomiting headache & HTN HTN HTN HTN HTN & blurred vision

Neurological signs gen seiz confusion gen seiz gen seiz gen seiz blurred vision

Acute treatment LOR
P
PB
mannitol* LOR
P
LOR
P
LOR
P
mannitol*

Chronic treatment P
PB
none P P P P
CLO

Outcome (day last follow-up Alive & well
(+1065)
Alive & well
(+1059)
Alive & well
(+1005)
Alive & well
(+760)
Died, grade IV GVHD (+60) Alive & well
(+320)

Mg = magnesium

HTN = arterial hypertension

gen seiz = generalized seizures

LOR = lorazepam 0.05 mg/kg/dose iv

P = phenitoyn 15 mg/kg/dose iv for acute treatment

phenitoyn 7 mg/kg/day iv for maintenance treatment

PB = Phenobarbital 7 mg/kg/day iv

* 0.5 g/kg/dose iv

CLO = oral clonazepam 0.05 mg/kg/day